Frequently Asked Questions
What is Welichem’s business?
- Developing and commercializing new therapeutics for autoimmune/ inflammatory diseases and cancer.
- Producing better therapeutics based on a novel source of compounds from symbiotic microorganisms.
- Unique compounds discovered by Welichem principals, leading scientists in symbiotic microorganisms, through more than 25 years of research.
What are the key elements of Welichem’s technology?
- Compounds have exceptionally effective bioactivities - immunomodulation & anti-proliferative.
- Existing evidence shows high efficacy with low or no toxicity.
- Compounds originate from natural process that has existed for millions of years – less likelihood of unknowns to occur through clinical trials.
- Pipeline of other ultra high quality drug leads – technology has already yielded many bioactive, small molecules in over 10 different classes of chemicals that exhibit a range of anti-inflammatory, antimicrobial and anti-proliferative (i.e. anti-cancer and anti-psoriatic) bioactivities.
What is Welichem’s market focus?
- Large target Markets with unmet needs.
- Psoriasis $4.4 billion.
- Eczema $4.0 billion.
- Potential for Inflammatory bowel diseases (IBD) - $1.6 billion.
What stage is Welichem at?
- First drug candidate is halfway through preclinical development.
- Our second drug candidate will be focused on cancer, another kind of cell proliferative disease.
What are Welichem’s competitive advantages?
- Compared with existing drugs, Welichem’s therapeutics offer the potential of safer treatments with greater efficacy and faster relief.
What is Welichem’s commercialization strategy?
- Complete development to clinical phase II.
- License to Pharma for upfront & milestone payments, then ongoing royalties.
- Budget of $12 million to complete Phase II clinical trials.
|